Prelude Therapeutics Incorporated Share Price
NASDAQ: PRLD | Small CapPrelude Therapeutics Incorporated Stock Performance
Open $5.22 | Prev. Close $5.71 | Circuit Range N/A |
Day Range $5.20 - $5.59 | Year Range $0.86 - $5.88 | Volume 22,593 |
Average Traded $5.41 |
Prelude Therapeutics Incorporated Share Price Today
As of 17 August 2026, Prelude Therapeutics Incorporated's share price is $5.54. The stock opened at $5.22, compared to its previous close of $5.71. During today's trading session, Prelude Therapeutics Incorporated's share price traded between $5.20 and $5.59, with an average price of $5.39. Over the past 52 weeks, the stock has recorded a high of $5.88 and a low of $0.86. In terms of performance, Prelude Therapeutics Incorporated's share price has risen by 100.72% over the last six months and is up 346.77% on a year-on-year basis.
Prelude Therapeutics Incorporated Share Price Chart
Prelude Therapeutics Incorporated Stock Fundamentals & Key Indicators
Market Cap $426.34M | PE Ratio (TTM) -4.29 | Dividend Yield N/A |
EPS (TTM) $-1.29 | Revenue (TTM) $12.14M | Return On Equity (TTM) -144.96% |
Profit Margin -819.59% | Debt to Equity 0.77 | Quarterly Earnings Growth YoY N/A |
Prelude Therapeutics Incorporated Quarterly Profit & Loss
All figures in USD
Prelude Therapeutics Incorporated Annual Profit & Loss
All figures in USD
About Prelude Therapeutics Incorporated
Prelude Therapeutics Incorporated, a clinical-stage precision oncology company, focuses on the discovery and development of novel precision cancer medicines to underserved patients. It is developing PRT3789, a selective degrader of SMARCA2 protein for the treatment of advanced or metastatic solid tumors with loss of SMARCA4 due to truncating mutation and/or deletion; PRT7732, a selective and orally bioavailable SMARCA2 degraders to treat advanced or metastatic solid tumors; and PRT2527, a cyclin-dependent kinase 9 inhibitor for the treatment of advanced solid tumors. The company's CDK9 program is a regulator of cancer-promoting transcriptional programs, including MCL1, MYC, and MYB. Prelude Therapeutics Incorporated was incorporated in 2016 and is based in Wilmington, Delaware.
Prelude Therapeutics Incorporated Historical Returns
| Month | Open | Close | Change % |
|---|---|---|---|
Aug 2026 | $4.61 | $5.54 | +20.17% |
Jul 2026 | $5.27 | $4.61 | -13.26% |
Jun 2026 | $3.86 | $5.32 | +35.24% |
May 2026 | $5.01 | $3.93 | -24.28% |
Apr 2026 | $3.60 | $5.19 | +52.65% |
Mar 2026 | $2.74 | $3.40 | +23.19% |
Feb 2026 | $1.88 | $2.76 | +48.39% |
Jan 2026 | $2.80 | $1.86 | -35.64% |
Dec 2025 | $1.52 | $2.89 | +72.54% |
Nov 2025 | $1.62 | $1.68 | +5.35% |
Oct 2025 | $1.62 | $1.59 | +10.42% |
Sep 2025 | $1.16 | $1.44 | +16.13% |
PRLD Share Price FAQs
What is Prelude Therapeutics Incorporated share price today?
What is the 52 week high and 52 week low of Prelude Therapeutics Incorporated stock?
What is PRLD's market capitalisation today?
What is PRLD's net income for the last quarter?
What is the 5 year returns of PRLD?
What is the high & low stock price of PRLD today?
Can I buy PRLD shares in India?